Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report
To report a case of second-degree atrioventricular block associated with concomitant use of aprepitant and amlodipine. A 73-year-old man with lung cancer was treated with aprepitant for prophylactic use for the prevention of nausea and vomiting, concomitantly with cisplatin, gemcitabine, and an inve...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical pharmacology and therapeutics 2021-04, Vol.59 (4), p.328-332 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 332 |
|---|---|
| container_issue | 4 |
| container_start_page | 328 |
| container_title | International journal of clinical pharmacology and therapeutics |
| container_volume | 59 |
| creator | Hibino, Hideyuki Makino, Yoshinori Sakiyama, Naomi Makihara-Ando, Reiko Hashimoto, Hironobu Akiyoshi, Takeshi Imaoka, Ayuko Fujiwara, Yutaka Ohe, Yuichiro Yamaguchi, Masakazu Ohtani, Hisakazu |
| description | To report a case of second-degree atrioventricular block associated with concomitant use of aprepitant and amlodipine.
A 73-year-old man with lung cancer was treated with aprepitant for prophylactic use for the prevention of nausea and vomiting, concomitantly with cisplatin, gemcitabine, and an investigational drug (anti-epidermal growth factor receptor monoclonal antibody). He was diagnosed with first-degree atrioventricular block and was taking amlodipine for hypertension. During the first cycle of chemotherapy, 5 days after the start of aprepitant, he experienced Wenckebach second-degree atrioventricular block (Mobitz type I), and amlodipine was discontinued. After day 6, the atrioventricular block was not shown. According to the Naranjo adverse drug reaction scale, a score of 7 was obtained (causality: probable). In addition, using the Drug Interaction Probability Scale, a score of 6 was obtained (causality: probable).
The drug-drug interaction between aprepitant and amlodipine was considered to have deteriorated his atrioventricular block, conceivably due to the inhibition of cytochrome P450 (CYP) 3A-mediated metabolism of amlodipine by aprepitant. |
| doi_str_mv | 10.5414/CP203758 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2505079833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2505079833</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-82eaa3843d135d80db7cadcc68cf97cc97941b156d0ea5bc22e6125424cf694d3</originalsourceid><addsrcrecordid>eNo9kElOxDAQRb0AMTRInABZYsOmwY7tDOxQi0lCggWso0rZATdpO9gOwyG4A2fhZAS6YVWbV_9Jj5A9zo6U5PJ4dpsxUahyjWyxSuZTXuVqk2zHOGcsU6qoNsimEEIpVsot8nH2BmhCA8l6R31LIQXrX4wbDw4dBNp0Hp8oxOjRQjKavtr0SNE79AubwCU6RPP7uei8tr11hoLTFPpg-iVgHQXaDe6BIrjRRvtRNypO6OnXJ0I0X58j60PaIestdNHsru6E3J-f3c0up9c3F1ez0-spCs7TtMwMgCil0FwoXTLdFAgaMS-xrQrEqqgkb7jKNTOgGswyk_NMyUxim1dSiwk5WO72wT8PJqZ67ofgRmWdKaZYUZVjogk5XFIYfIzBtHUf7ALCe81Z_dO6_ms9ovurwaFZGP0P_oUW3xVjf1o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2505079833</pqid></control><display><type>article</type><title>Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Hibino, Hideyuki ; Makino, Yoshinori ; Sakiyama, Naomi ; Makihara-Ando, Reiko ; Hashimoto, Hironobu ; Akiyoshi, Takeshi ; Imaoka, Ayuko ; Fujiwara, Yutaka ; Ohe, Yuichiro ; Yamaguchi, Masakazu ; Ohtani, Hisakazu</creator><creatorcontrib>Hibino, Hideyuki ; Makino, Yoshinori ; Sakiyama, Naomi ; Makihara-Ando, Reiko ; Hashimoto, Hironobu ; Akiyoshi, Takeshi ; Imaoka, Ayuko ; Fujiwara, Yutaka ; Ohe, Yuichiro ; Yamaguchi, Masakazu ; Ohtani, Hisakazu</creatorcontrib><description>To report a case of second-degree atrioventricular block associated with concomitant use of aprepitant and amlodipine.
A 73-year-old man with lung cancer was treated with aprepitant for prophylactic use for the prevention of nausea and vomiting, concomitantly with cisplatin, gemcitabine, and an investigational drug (anti-epidermal growth factor receptor monoclonal antibody). He was diagnosed with first-degree atrioventricular block and was taking amlodipine for hypertension. During the first cycle of chemotherapy, 5 days after the start of aprepitant, he experienced Wenckebach second-degree atrioventricular block (Mobitz type I), and amlodipine was discontinued. After day 6, the atrioventricular block was not shown. According to the Naranjo adverse drug reaction scale, a score of 7 was obtained (causality: probable). In addition, using the Drug Interaction Probability Scale, a score of 6 was obtained (causality: probable).
The drug-drug interaction between aprepitant and amlodipine was considered to have deteriorated his atrioventricular block, conceivably due to the inhibition of cytochrome P450 (CYP) 3A-mediated metabolism of amlodipine by aprepitant.</description><identifier>ISSN: 0946-1965</identifier><identifier>DOI: 10.5414/CP203758</identifier><identifier>PMID: 33355084</identifier><language>eng</language><publisher>Germany: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG</publisher><subject>Aged ; Amlodipine - adverse effects ; Antiemetics ; Aprepitant - therapeutic use ; Atrioventricular Block - chemically induced ; Blood pressure ; Cancer therapies ; Case reports ; Chemotherapy ; Cytochrome ; Drug interactions ; Electrocardiography ; Enzymes ; Epidermal growth factor ; Humans ; Hypertension ; Laboratories ; Lung cancer ; Lung Neoplasms - complications ; Lung Neoplasms - drug therapy ; Male ; Morpholines - adverse effects ; Patients ; Pharmacy ; Potassium ; Uric acid ; Vomiting</subject><ispartof>International journal of clinical pharmacology and therapeutics, 2021-04, Vol.59 (4), p.328-332</ispartof><rights>Copyright Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG Apr 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-82eaa3843d135d80db7cadcc68cf97cc97941b156d0ea5bc22e6125424cf694d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33355084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hibino, Hideyuki</creatorcontrib><creatorcontrib>Makino, Yoshinori</creatorcontrib><creatorcontrib>Sakiyama, Naomi</creatorcontrib><creatorcontrib>Makihara-Ando, Reiko</creatorcontrib><creatorcontrib>Hashimoto, Hironobu</creatorcontrib><creatorcontrib>Akiyoshi, Takeshi</creatorcontrib><creatorcontrib>Imaoka, Ayuko</creatorcontrib><creatorcontrib>Fujiwara, Yutaka</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Yamaguchi, Masakazu</creatorcontrib><creatorcontrib>Ohtani, Hisakazu</creatorcontrib><title>Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report</title><title>International journal of clinical pharmacology and therapeutics</title><addtitle>Int J Clin Pharmacol Ther</addtitle><description>To report a case of second-degree atrioventricular block associated with concomitant use of aprepitant and amlodipine.
A 73-year-old man with lung cancer was treated with aprepitant for prophylactic use for the prevention of nausea and vomiting, concomitantly with cisplatin, gemcitabine, and an investigational drug (anti-epidermal growth factor receptor monoclonal antibody). He was diagnosed with first-degree atrioventricular block and was taking amlodipine for hypertension. During the first cycle of chemotherapy, 5 days after the start of aprepitant, he experienced Wenckebach second-degree atrioventricular block (Mobitz type I), and amlodipine was discontinued. After day 6, the atrioventricular block was not shown. According to the Naranjo adverse drug reaction scale, a score of 7 was obtained (causality: probable). In addition, using the Drug Interaction Probability Scale, a score of 6 was obtained (causality: probable).
The drug-drug interaction between aprepitant and amlodipine was considered to have deteriorated his atrioventricular block, conceivably due to the inhibition of cytochrome P450 (CYP) 3A-mediated metabolism of amlodipine by aprepitant.</description><subject>Aged</subject><subject>Amlodipine - adverse effects</subject><subject>Antiemetics</subject><subject>Aprepitant - therapeutic use</subject><subject>Atrioventricular Block - chemically induced</subject><subject>Blood pressure</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Cytochrome</subject><subject>Drug interactions</subject><subject>Electrocardiography</subject><subject>Enzymes</subject><subject>Epidermal growth factor</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Laboratories</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Morpholines - adverse effects</subject><subject>Patients</subject><subject>Pharmacy</subject><subject>Potassium</subject><subject>Uric acid</subject><subject>Vomiting</subject><issn>0946-1965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kElOxDAQRb0AMTRInABZYsOmwY7tDOxQi0lCggWso0rZATdpO9gOwyG4A2fhZAS6YVWbV_9Jj5A9zo6U5PJ4dpsxUahyjWyxSuZTXuVqk2zHOGcsU6qoNsimEEIpVsot8nH2BmhCA8l6R31LIQXrX4wbDw4dBNp0Hp8oxOjRQjKavtr0SNE79AubwCU6RPP7uei8tr11hoLTFPpg-iVgHQXaDe6BIrjRRvtRNypO6OnXJ0I0X58j60PaIestdNHsru6E3J-f3c0up9c3F1ez0-spCs7TtMwMgCil0FwoXTLdFAgaMS-xrQrEqqgkb7jKNTOgGswyk_NMyUxim1dSiwk5WO72wT8PJqZ67ofgRmWdKaZYUZVjogk5XFIYfIzBtHUf7ALCe81Z_dO6_ms9ovurwaFZGP0P_oUW3xVjf1o</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Hibino, Hideyuki</creator><creator>Makino, Yoshinori</creator><creator>Sakiyama, Naomi</creator><creator>Makihara-Ando, Reiko</creator><creator>Hashimoto, Hironobu</creator><creator>Akiyoshi, Takeshi</creator><creator>Imaoka, Ayuko</creator><creator>Fujiwara, Yutaka</creator><creator>Ohe, Yuichiro</creator><creator>Yamaguchi, Masakazu</creator><creator>Ohtani, Hisakazu</creator><general>Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202104</creationdate><title>Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report</title><author>Hibino, Hideyuki ; Makino, Yoshinori ; Sakiyama, Naomi ; Makihara-Ando, Reiko ; Hashimoto, Hironobu ; Akiyoshi, Takeshi ; Imaoka, Ayuko ; Fujiwara, Yutaka ; Ohe, Yuichiro ; Yamaguchi, Masakazu ; Ohtani, Hisakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-82eaa3843d135d80db7cadcc68cf97cc97941b156d0ea5bc22e6125424cf694d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Amlodipine - adverse effects</topic><topic>Antiemetics</topic><topic>Aprepitant - therapeutic use</topic><topic>Atrioventricular Block - chemically induced</topic><topic>Blood pressure</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Cytochrome</topic><topic>Drug interactions</topic><topic>Electrocardiography</topic><topic>Enzymes</topic><topic>Epidermal growth factor</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Laboratories</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Morpholines - adverse effects</topic><topic>Patients</topic><topic>Pharmacy</topic><topic>Potassium</topic><topic>Uric acid</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hibino, Hideyuki</creatorcontrib><creatorcontrib>Makino, Yoshinori</creatorcontrib><creatorcontrib>Sakiyama, Naomi</creatorcontrib><creatorcontrib>Makihara-Ando, Reiko</creatorcontrib><creatorcontrib>Hashimoto, Hironobu</creatorcontrib><creatorcontrib>Akiyoshi, Takeshi</creatorcontrib><creatorcontrib>Imaoka, Ayuko</creatorcontrib><creatorcontrib>Fujiwara, Yutaka</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Yamaguchi, Masakazu</creatorcontrib><creatorcontrib>Ohtani, Hisakazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hibino, Hideyuki</au><au>Makino, Yoshinori</au><au>Sakiyama, Naomi</au><au>Makihara-Ando, Reiko</au><au>Hashimoto, Hironobu</au><au>Akiyoshi, Takeshi</au><au>Imaoka, Ayuko</au><au>Fujiwara, Yutaka</au><au>Ohe, Yuichiro</au><au>Yamaguchi, Masakazu</au><au>Ohtani, Hisakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report</atitle><jtitle>International journal of clinical pharmacology and therapeutics</jtitle><addtitle>Int J Clin Pharmacol Ther</addtitle><date>2021-04</date><risdate>2021</risdate><volume>59</volume><issue>4</issue><spage>328</spage><epage>332</epage><pages>328-332</pages><issn>0946-1965</issn><abstract>To report a case of second-degree atrioventricular block associated with concomitant use of aprepitant and amlodipine.
A 73-year-old man with lung cancer was treated with aprepitant for prophylactic use for the prevention of nausea and vomiting, concomitantly with cisplatin, gemcitabine, and an investigational drug (anti-epidermal growth factor receptor monoclonal antibody). He was diagnosed with first-degree atrioventricular block and was taking amlodipine for hypertension. During the first cycle of chemotherapy, 5 days after the start of aprepitant, he experienced Wenckebach second-degree atrioventricular block (Mobitz type I), and amlodipine was discontinued. After day 6, the atrioventricular block was not shown. According to the Naranjo adverse drug reaction scale, a score of 7 was obtained (causality: probable). In addition, using the Drug Interaction Probability Scale, a score of 6 was obtained (causality: probable).
The drug-drug interaction between aprepitant and amlodipine was considered to have deteriorated his atrioventricular block, conceivably due to the inhibition of cytochrome P450 (CYP) 3A-mediated metabolism of amlodipine by aprepitant.</abstract><cop>Germany</cop><pub>Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG</pub><pmid>33355084</pmid><doi>10.5414/CP203758</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0946-1965 |
| ispartof | International journal of clinical pharmacology and therapeutics, 2021-04, Vol.59 (4), p.328-332 |
| issn | 0946-1965 |
| language | eng |
| recordid | cdi_proquest_journals_2505079833 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Amlodipine - adverse effects Antiemetics Aprepitant - therapeutic use Atrioventricular Block - chemically induced Blood pressure Cancer therapies Case reports Chemotherapy Cytochrome Drug interactions Electrocardiography Enzymes Epidermal growth factor Humans Hypertension Laboratories Lung cancer Lung Neoplasms - complications Lung Neoplasms - drug therapy Male Morpholines - adverse effects Patients Pharmacy Potassium Uric acid Vomiting |
| title | Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A45%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exacerbation%20of%20atrioventricular%20block%20associated%20with%20concomitant%20use%20of%20amlodipine%20and%20aprepitant%20in%20a%20lung%20cancer%20patient:%20A%C2%A0case%C2%A0report&rft.jtitle=International%20journal%20of%20clinical%20pharmacology%20and%20therapeutics&rft.au=Hibino,%20Hideyuki&rft.date=2021-04&rft.volume=59&rft.issue=4&rft.spage=328&rft.epage=332&rft.pages=328-332&rft.issn=0946-1965&rft_id=info:doi/10.5414/CP203758&rft_dat=%3Cproquest_cross%3E2505079833%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2505079833&rft_id=info:pmid/33355084&rfr_iscdi=true |